Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy.

Richardson F, Young GD, Sennello R, Wolf J, Argast GM, Mercado P, Davies A, Epstein DM, Wacker B.

Anticancer Res. 2012 Feb;32(2):537-52.

PMID:
22287743
2.

Inducible expression of TGFβ, snail and Zeb1 recapitulates EMT in vitro and in vivo in a NSCLC model.

Argast GM, Krueger JS, Thomson S, Sujka-Kwok I, Carey K, Silva S, O'Connor M, Mercado P, Mulford IJ, Young GD, Sennello R, Wild R, Pachter JA, Kan JL, Haley J, Rosenfeld-Franklin M, Epstein DM.

Clin Exp Metastasis. 2011 Oct;28(7):593-614. doi: 10.1007/s10585-011-9394-8. Epub 2011 Jun 4.

PMID:
21643654
3.

A systems view of epithelial-mesenchymal transition signaling states.

Thomson S, Petti F, Sujka-Kwok I, Mercado P, Bean J, Monaghan M, Seymour SL, Argast GM, Epstein DM, Haley JD.

Clin Exp Metastasis. 2011 Feb;28(2):137-55. doi: 10.1007/s10585-010-9367-3. Epub 2010 Dec 31.

4.

Cooperative signaling between oncostatin M, hepatocyte growth factor and transforming growth factor-β enhances epithelial to mesenchymal transition in lung and pancreatic tumor models.

Argast GM, Mercado P, Mulford IJ, O'Connor M, Keane DM, Shaaban S, Epstein DM, Pachter JA, Kan JL.

Cells Tissues Organs. 2011;193(1-2):114-32. doi: 10.1159/000320179. Epub 2010 Nov 2.

PMID:
21041998
5.

Inactivation of p38 MAPK during liver regeneration.

Campbell JS, Argast GM, Yuen SY, Hayes B, Fausto N.

Int J Biochem Cell Biol. 2011 Feb;43(2):180-8. doi: 10.1016/j.biocel.2010.08.002. Epub 2010 Aug 11.

6.

A mediator of Rho-dependent invasion moonlights as a methionine salvage enzyme.

Kabuyama Y, Litman ES, Templeton PD, Metzner SI, Witze ES, Argast GM, Langer SJ, Polvinen K, Shellman Y, Chan D, Shabb JB, Fitzpatrick JE, Resing KA, Sousa MC, Ahn NG.

Mol Cell Proteomics. 2009 Oct;8(10):2308-20. doi: 10.1074/mcp.M900178-MCP200. Epub 2009 Jul 20.

7.

Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cells.

Argast GM, Croy CH, Couts KL, Zhang Z, Litman E, Chan DC, Ahn NG.

Oncogene. 2009 Jul 30;28(30):2697-709. doi: 10.1038/onc.2009.133. Epub 2009 Jun 1.

8.

Wnt5a control of cell polarity and directional movement by polarized redistribution of adhesion receptors.

Witze ES, Litman ES, Argast GM, Moon RT, Ahn NG.

Science. 2008 Apr 18;320(5874):365-9. doi: 10.1126/science.1151250.

9.

Inhibition of RIP2/RIck/CARDIAK activity by pyridinyl imidazole inhibitors of p38 MAPK.

Argast GM, Fausto N, Campbell JS.

Mol Cell Biochem. 2005 Jan;268(1-2):129-40.

PMID:
15724446
10.

Epidermal growth factor receptor transactivation mediates tumor necrosis factor-induced hepatocyte replication.

Argast GM, Campbell JS, Brooling JT, Fausto N.

J Biol Chem. 2004 Aug 13;279(33):34530-6. Epub 2004 Jun 15.

11.

Expression of suppressors of cytokine signaling during liver regeneration.

Campbell JS, Prichard L, Schaper F, Schmitz J, Stephenson-Famy A, Rosenfeld ME, Argast GM, Heinrich PC, Fausto N.

J Clin Invest. 2001 May;107(10):1285-92.

12.

I-PpoI and I-CreI homing site sequence degeneracy determined by random mutagenesis and sequential in vitro enrichment.

Argast GM, Stephens KM, Emond MJ, Monnat RJ Jr.

J Mol Biol. 1998 Jul 17;280(3):345-53.

PMID:
9665841
13.

The mitogen-activated protein kinase pathway can mediate growth inhibition and proliferation in smooth muscle cells. Dependence on the availability of downstream targets.

Bornfeldt KE, Campbell JS, Koyama H, Argast GM, Leslie CC, Raines EW, Krebs EG, Ross R.

J Clin Invest. 1997 Aug 15;100(4):875-85.

14.

Expression and characterization of glycogen synthase kinase-3 mutants and their effect on glycogen synthase activity in intact cells.

Eldar-Finkelman H, Argast GM, Foord O, Fischer EH, Krebs EG.

Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10228-33.

15.

Platelet-derived growth factor stimulates protein kinase A through a mitogen-activated protein kinase-dependent pathway in human arterial smooth muscle cells.

Graves LM, Bornfeldt KE, Sidhu JS, Argast GM, Raines EW, Ross R, Leslie CC, Krebs EG.

J Biol Chem. 1996 Jan 5;271(1):505-11.

16.

cAMP- and rapamycin-sensitive regulation of the association of eukaryotic initiation factor 4E and the translational regulator PHAS-I in aortic smooth muscle cells.

Graves LM, Bornfeldt KE, Argast GM, Krebs EG, Kong X, Lin TA, Lawrence JC Jr.

Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7222-6.

Supplemental Content

Loading ...
Support Center